ReviewFrontiers in immunology2023
The role of nanotherapy in head and neck squamous cell carcinoma by targeting tumor microenvironment.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 14 citations in OpenAlex.
- Single-cell transcriptomics reveals heterogeneity and immune microenvironment in lymphatic metastasis of head and neck squamous cell carcinoma.Genes and immunity · 2026Article
- Cancer metabolism: bridging tumorigenesis mechanisms to treatment susceptibility.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- The Role of miRNAs in Regulating Neurovascular Unit Homeostasis: Bidirectional Communication and Therapeutic Insights in Ischemic Stroke.International journal of molecular sciences · 2026Review
- Advanced nanotechnology in enhancing immune checkpoint inhibitors (ICIs) for head and neck cancer therapy.Cell communication and signaling : CCS · 2025Review
- AI-driven multi-omics integration of cancer-associated fibroblasts for prognostic modeling and therapeutic target discovery in head and neck squamous cell carcinoma.NPJ precision oncology · 2025Article
- Molecular Targets for Pharmacotherapy of Head and Neck Squamous Cell Carcinomas.Current issues in molecular biology · 2025Review
- Current nano drug delivery systems for targeting head and neck squamous cell carcinoma microenvironment: a narrative review.Molecular biology reports · 2025Review
- Nanotechnology in the perioperative treatment of head and neck cancer: application and outlook.Frontiers in bioengineering and biotechnology · 2025Review
- Chemotherapy-free innovations in locally advanced head and neck cancer: a comprehensive review.Frontiers in oncology · 2025Review
- Review
- Precision USPIO-PEG-SLeInternational journal of nanomedicine · 2024Article
- Role of Microenvironmental Components in Head and Neck Squamous Cell Carcinoma.Journal of personalized medicine · 2023Review
- Lipid-Coated Polymeric Nanoparticles for the Photodynamic Therapy of Head and Neck Squamous Cell Carcinomas.Pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck squamous cell carcinomas (HNSCCs) refers to a group of highly malignant and pathogenically complex tumors. Traditional treatment methods include surgery, radiotherapy, and chemotherapy. However, with advancements in genetics, molecular medicine, and nanotherapy, more effective and safer treatments have been developed. Nanotherapy, in particular, has the potential to be an alternative therapeutic option for HNSCC patients, given its advantageous targeting capabilities, low toxicity and modifiability. Recent research has highlighted the important role of the tumor microenvironment (TME) in the development of HNSCC. The TME is composed of various cellular components, such as fibroblasts, vascular endothelial cells, and immune cells, as well as non-cellular agents such as cytokines, chemokines, growth factors, extracellular matrix (ECM), and extracellular vesicles (EVs). These components greatly influence the prognosis and therapeutic efficacy of HNSCC, making the TME a potential target for treatment using nanotherapy. By regulating angiogenesis, immune response, tumor metastasis and other factors, nanotherapy can potentially alleviate HNSCC symptoms. This review aims to summarize and discuss the application of nanotherapy that targets HNSCC's TME. We highlight the therapeutic value of nanotherapy for HNSCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.